Learning Module Overview for:
Treatment of Invasive Aspergillosis

View the complete offering
of Learning Modules

Registration Required
To access CME activities and to view your personalized CME Profile page, which tracks completed learning modules, post-test scores and CME credits earned, and allows you to download printable CME certificates.

Send us your comments
We welcome your feedback and / or questions related to the educational content provided through Mechanisms in Fungal Infections.

Release date: January 19, 2009
Expiration date: January 19, 2010

Click here to view Technical Requirements

Target Audience
This learning activity is intended for oncologists, hematologists, infectious disease specialists who treat transplant patients and other patient populations at risk for developing fungal infections.

Learning Objectives
After completing this educational activity, the learner should be better able to:
  • Review the guidelines for the treatment of the invasive infections caused by Aspergillus species.
  • Describe the value of Amphotericin B (AmB), lipid formulations of AmB, itraconazole, posaconazole, voriconazole, caspofungin, anidulafungin, and micafungin in the treatment of invasive aspergillosis.
  • Recognize that treatment options differ between various infection sites and that surgical intervention can be a critical component of therapy.
  • Discuss the importance of reversal of immunosuppression and close monitoring in the management of invasive aspergillosis.
Thomas F. Patterson, MD, FACP
Professor of Medicine
Chief, Division of Infectious Diseases
Director, San Antonio Center for Medical Mycology
University of Texas Health Science Center at San Antonio
San Antonio, Texas

George R. Thompson III, MD
University of Texas Health Science Center at San Antonio
San Antonio, Texas

Disclosure of Financial Interests
As an accredited provider of continuing medical education, Imedex, LLC is required to ask authors to disclose any real or apparent conflict of interest they may have as related to the content of their chapter(s). The existence of commercial or financial interests of speakers related to the subject matter of their chapter(s) should not be construed as implying bias or decreasing the value of their chapter(s). However, the disclosure should help participants form their own judgments.

All authors were independently selected by the organizing committee. Those authors who disclosed affiliations or financial interests with the commercial organizations involved with products, to which the may refer are listed below.

1 = grant research
2 = consultant
3 = speaker’s bureau
4 = stock shareholder
5 = other support

Dr Thomas F. Patterson
Supporters of this activity:
Astellas Pharma US, Inc.1
Pfizer Inc1,2,3

Other affiliations:
Basilea Pharmaceutica Ltd.1,2,3
MERCK & CO., Inc.2,3

Dr George R. Thompson III
Dr Thompson reports no affiliations with the supporters of this activity.

Other affiliations:
Basilea Pharmaceutica Ltd.1

Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Specialty Group, which is a subsidiary of AmerisourceBergen Company. All Imedex staff members, except for the following, who are in a position to control the content of this activity, have no financial relationships with any commercial interests that are relevant to this activity:

Keith Steward, MD, MBA, owns shares of Pfizer Inc and Johnson & Johnson, as well as stock options for AmerisourceBergen.

Chris Bolwell owns shares of GlaxoSmithKline and stock options for AmerisourceBergen.

Bradley Bongiovanni, ND, Becky Lynch, RN, Emily Geiger, and Don Harting, MA, ELS own stock options for AmerisourceBergen.

Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA has regulatory authority.

Disclosure of Unapproved Uses and Investigational Drugs
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

Statement of Commercial Support
The following companies have provided unrestricted educational grants in support of this activity: Astellas Pharma US, Inc. and Pfizer Inc.

(*Please check this box to proceed - required)

About Us | Contact Us | Terms of Use | Privacy Policy | Technical Requirements | Site Map | Help